DYAI (Dyadic International) Debt-to-Asset : 0.50 (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Dyadic International Debt-to-Asset?

Dyadic International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.05 Mil. Dyadic International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.32 Mil. Dyadic International's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $10.81 Mil. Dyadic International's debt to asset for the quarter that ended in Sep. 2024 was 0.50.

Dyadic International Debt-to-Asset Historical Data

The historical data trend for Dyadic International's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International Debt-to-Asset Chart

Dyadic International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

Dyadic International Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.02	0.02	0.47	0.52	0.50

Competitive Comparison of Dyadic International's Debt-to-Asset

For the Biotechnology subindustry, Dyadic International's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyadic International's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Dyadic International's Debt-to-Asset falls into.

Dyadic International Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Dyadic International's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.048	+	0.089)	/	8.219
	=	0.02

Dyadic International's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.053	+	5.316)	/	10.806
	=	0.50

Dyadic International (NAS:DYAI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Dyadic International Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Dyadic International's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyadic International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1044 North U.S. Highway One, Suite 201, Jupiter, FL, USA, 33477

Website

https://www.dyadic.com

Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Executives

Ronen Tchelet	officer: VP of Research and Bus. Dvlpmt	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb	director, 10 percent owner, officer: President, CEO & Chairman	C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton	officer: Chief Business Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996	10 percent owner	C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones	officer: Managing Dir of BD & Licensing	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst	director	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland	director	C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson	officer: Chief Financial Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok	director	KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose	director	4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson	10 percent owner	1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020